行业首创！福瑞达珂谧发布穿膜胶原重大技术成果

Core Viewpoint - The launch of the innovative transdermal collagen technology by Furuida Biotech's brand KeyC marks a significant advancement in the field of recombinant collagen protein, enhancing skin penetration rates by 27.5 times compared to traditional methods, indicating a disruptive innovation in the industry [1][4]. Group 1: Technology and Innovation - The newly developed transdermal collagen technology allows for significantly improved skin penetration, overcoming the traditional barrier that large molecular collagen could not penetrate the stratum corneum [3][4]. - The research team utilized cell-penetrating peptides to link with recombinant type III collagen, effectively delivering collagen to deeper skin layers, akin to a vehicle transporting goods [3][4]. - Experimental data shows that the transdermal collagen significantly enhances the expression of key structural proteins in the skin, promoting repair and regeneration, thus providing a comprehensive anti-aging effect [4]. Group 2: Product Launch and Efficacy - Furuida Biotech has launched a series of products featuring the new transdermal collagen, including a collagen essence and a collagen mask, which have shown promising results in reducing fine lines and improving skin texture [5]. - Third-party SGS certification indicates that after 10 minutes of application, fine lines between the eyebrows were reduced by 13.15%, and after 28 days, the reduction reached 23.24% [5]. Group 3: Market Position and Strategy - Furuida Biotech aims to leverage its research capabilities and industry leadership to establish recombinant collagen as a significant growth segment, following the success of hyaluronic acid [7]. - The company plans to enhance its investment in the medical beauty brand KeyC and strengthen collaborations with research institutions and hospitals to capitalize on the emerging opportunities in the recombinant collagen market [7].